Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Clodronate in hypercalcemia of malignancy.

J P Bonjour1, R Rizzoli

  • 1Department of Medicine, University Hospital, Geneva, Switzerland.

Calcified Tissue International
|January 1, 1990
PubMed
Summary

Clodronate effectively normalizes plasma calcium in most cancer patients with hypercalcemia by reducing bone resorption. However, some patients require additional therapies targeting renal calcium reabsorption for complete treatment.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Fracture history of healthy premenopausal women is associated with a reduction of cortical microstructural components at the distal radius.

Bone·2013
Same author

Fractures in healthy females followed from childhood to early adulthood are associated with later menarcheal age and with impaired bone microstructure at peak bone mass.

The Journal of clinical endocrinology and metabolism·2012
Same author

Fractures during childhood and adolescence in healthy boys: relation with bone mass, microstructure, and strength.

The Journal of clinical endocrinology and metabolism·2011
Same author

Pubertal timing and body mass index gain from birth to maturity in relation with femoral neck BMD and distal tibia microstructure in healthy female subjects.

Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA·2011
Same author

The influence of pubertal timing on bone mass acquisition: a predetermined trajectory detectable five years before menarche.

The Journal of clinical endocrinology and metabolism·2009
Same author

Nutrition and aging. The Carla Workshop.

The journal of nutrition, health & aging·2008

Area of Science:

  • Oncology
  • Pharmacology
  • Endocrinology

Background:

  • Hypercalcemia of malignancy is a common complication.
  • Clodronate, a diphosphonate, is a primary treatment for hypercalcemia due to increased bone resorption.
  • The efficacy of clodronate can be limited in certain patient subsets.

Purpose of the Study:

  • To evaluate the effectiveness of clodronate in managing hypercalcemia of malignancy.
  • To identify patient subgroups with varying responses to clodronate therapy.
  • To explore potential adjunctive therapies for refractory hypercalcemia.

Main Methods:

  • Intravenous administration of clodronate in hypercalcemic cancer patients.
  • Monitoring of plasma calcium levels and bone resorption markers.
  • Experimental models using parathyroid hormone-related peptide to simulate specific hypercalcemic mechanisms.

Main Results:

  • Clodronate normalized plasma calcium in most patients by reducing bone resorption within 3-5 days.
  • A subset of patients showed incomplete response due to increased renal calcium reabsorption.
  • Clodronate treatment led to increased parathyroid hormone and 1,25-dihydroxyvitamin D3 levels, preventing hypocalcemia.

Conclusions:

  • Clodronate is effective for hypercalcemia of malignancy driven by bone resorption.
  • Additional therapeutic strategies targeting renal calcium handling are needed for some patients.
  • Understanding calcium flux disturbances is crucial for optimizing treatment of cancer-related hypercalcemia.

Related Experiment Videos